{"news_desk": "Dealbook", "print_page": "2", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By AMIE TSANG and ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Amie", "organization": "", "lastname": "TSANG"}, {"rank": 2, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Novartis agrees to buy multiple sclerosis drug ofatumumab, sold under the name Arzerra, from GlaxoSmithKline for up to $1 billion.", "type_of_material": "News", "word_count": "528", "lead_paragraph": "The experimental drug ofatumumab would bolster the Swiss pharmaceutical company\u2019s portfolio of multiple sclerosis treatments.", "pub_date": "2015-08-22T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Novartis to Buy Multiple Sclerosis Drug From Glaxo", "print_headline": "Business Briefing; Novartis Buys Glaxo Multiple Sclerosis Drug"}, "snippet": "The experimental drug ofatumumab would bolster the Swiss pharmaceutical company\u2019s portfolio of multiple sclerosis treatments.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/08/22/business/dealbook/novartis-buys-glaxo-drug-for-1-billion.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "GlaxoSmithKline PLC", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Novartis AG", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Multiple Sclerosis", "name": "subject"}], "blog": [], "_id": "55d6e3cc38f0d81d6b2effea", "source": "The New York Times"}